Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine

Schizophrenia Research
Sridhar NatesanShitij Kapur

Abstract

Amisulpride's high and selective affinity for dopamine D2/3 (Ki 1.3/2.4 nM) receptors, lack of affinity for serotonin receptors, and its unusually high therapeutic doses (400-800 mg/day) makes it unique among atypical antipsychotics and prompted us to compare its actions with other antipsychotics in animal models. Amisulpride's effects on amphetamine and phencyclidine induced locomotor activity (AIL/PIL), conditioned avoidance response, catalepsy (CAT), subcortical Fos expression, and plasma prolactin was correlated to its time-course striatal D2/3 and prefrontal 5-HT2 receptor occupancy (D(2/3)/5-HT2RO); in comparison to haloperidol, clozapine, and risperidone. Unlike the atypicals clozapine and risperidone, amisulpride lacked 5-HT2RO and showed a 'delayed' pattern of D2/3RO: 43, 60 and 88% after 1, 2 and 6 h (100 mg/kg), respectively, despite a quick onset (1 h) and decline (6 h) of prolactin elevation. While haloperidol and risperidone were effective at D2RO>60%, clozapine at D2/3RO<50%, amisulpride was effective only when its D2RO exceeded 60% with a delayed latency and lasted longer than other antipsychotics. CAT was observed for haloperidol and risperidone when D2RO exceeded 80%, while in the case of amisulpride, CAT was ...Continue Reading

References

Jan 1, 1989·European Archives of Psychiatry and Neurological Sciences·H Y MeltzerS Matsubara
Sep 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A Carlsson
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Feb 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·M P MartresJ Costentin
Jun 1, 1994·Pharmacology, Biochemistry, and Behavior·D M JacksonA Bengtsson
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·V V RaoD Piwnica-Worms
Feb 2, 2002·The American Journal of Psychiatry·Stefan LeuchtWerner Kissling
Jul 30, 2002·European Journal of Pharmacology·Giorgio MarcheseLuca Pani
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Jul 17, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sebastian HärtterHans-Joachim Galla
Dec 20, 2003·Annals of the New York Academy of Sciences·Bita Moghaddam, Mark E Jackson
Mar 31, 2004·Cellular and Molecular Life Sciences : CMLS·P M Jones, A M George
Sep 24, 2004·Advanced Drug Delivery Reviews·Elizabeth C M de Lange
Feb 19, 2005·Psychopharmacology·James M StoneLyn S Pilowsky
Dec 2, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sridhar NatesanShitij Kapur
Mar 24, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jonathan D UrbanRichard B Mailman
Aug 29, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hao-Jie ZhuC Lindsay DeVane

❮ Previous
Next ❯

Citations

Jun 24, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Signe DüringBob Oranje
Aug 17, 2011·Indian Journal of Pharmacology·Murad Atmaca, Sevda Korkmaz
Dec 8, 2010·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Farhat BatoolDarakhshan Jabeen Haleem
Jan 5, 2013·Pharmacology, Biochemistry, and Behavior·Christina A Wilson, Alvin V Terry
Apr 22, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Thais Emanoelle T PompeuFrançois Noël
Jan 30, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Andrea de BartolomeisFelice Iasevoli
Dec 26, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Saki ShimizuYukihiro Ohno
Nov 9, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Carmine TomasettiAndrea de Bartolomeis
May 17, 2012·Pharmacology, Biochemistry, and Behavior·Barbara BrickerSeth Y Ablordeppey
Nov 23, 2010·The International Journal of Neuropsychopharmacology·Sridhar NatesanShitij Kapur
May 15, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Andrea de BartolomeisFelice Iasevoli
Jul 7, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Madeleine UysBrian H Harvey
Mar 24, 2017·Brain : a Journal of Neurology·Suzanne ReevesRobert Howard
May 8, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Philipp A CsomorFranz X Vollenweider
Dec 12, 2018·International Clinical Psychopharmacology·Unax LertxundiCarmelo Aguirre
May 27, 2010·Clinical Neuropharmacology·Artemios PehlivanidisGeorge N Papadimitriou
Jan 29, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Myrthala Juárez-TreviñoRosalinda Sepúlveda Sepúlveda
Feb 4, 2014·Reviews in the Neurosciences·Antonella Gasbarri, Assunta Pompili
Mar 15, 2015·Behavioural Pharmacology·Małgorzata HołujAgnieszka Nikiforuk
Jan 1, 2018·Open Access Journal of Translational Medicine & Research·Judith M Gault, Abraham M Nussbaum
Oct 17, 2020·European Journal of Pharmacology·Cristina CosiSilvia Gatti-McArthur

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.